Xcellerex’ tech key to US rapid vacc production project

By Staff Reporter

- Last updated on GMT

Related tags Influenza

Xcellerex’ development and bioprocess manufacturing technology plays key role in creation of rapid, low-cost vaccine production system.

The US biomanufacturing technology firm, and partners Pfenex, BioPharm Services and deltaDOT, were able to produce purified “swine flu” H1 hemagglutinin just 42 days starting with the protein’s amino acid sequence.

The project combined Xcellerex’ microbial PDMax process development and FlexFactory technology with expression, analysis and data modelling platforms to create a rapid-response vaccine production platform.

Company chief technology officer Parrish Galliher said that: “We are very pleased with the results of the test, which demonstrated the performance of rapid, flexible, and portable biomanufacturing.”

Galliher added that: “The results exceeded our expectations and we thank Pfenex, deltaDOT and BioPharm Services for their teamwork to achieve these outstanding results​.”

The co-developed production platform, which Xcellerex said bettered "the goal for rate of production by at least 10 fold and exceeded all product quality specifications​," has obvious application in the production of vaccines in the event of another influenza pandemic.

This point was stressed by the US Defense Advanced Research Projects Agency (DARPA) and Defense Threat Reduction Agency’s Transformational Medical Technologies Initiative (TMTI), which co-funded the work.

The test demonstrated the speed and capability of the platform in producing a real-world vaccine, in this case swine flu H1 within 12 weeks of receipt of an unknown target amino acid sequence.

The team succeeded in developing a strain and bioprocess, and fully characterizing the purified product in less than six weeks and at a cost, that scaled to manufacturing would be less than $0.50 per dose​.”

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 09-Jun-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...